Combination therapy for advanced urothelial cancer: LEAP-011 trial.
作者信息
Singh Kirti
机构信息
Department of Urology, AIIMS, Bhubaneswar, Odisha, India.
出版信息
Indian J Urol. 2024 Jul-Sep;40(3):203-204. doi: 10.4103/iju.iju_62_24. Epub 2024 Jul 1.
Abstract
摘要
相似文献
1
Combination therapy for advanced urothelial cancer: LEAP-011 trial.晚期尿路上皮癌的联合治疗：LEAP-011试验。
Indian J Urol. 2024 Jul-Sep;40(3):203-204. doi: 10.4103/iju.iju_62_24. Epub 2024 Jul 1.
2
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.帕博利珠单抗联合或不联合乐伐替尼作为晚期尿路上皮癌患者的一线治疗（LEAP-011）：一项3期随机双盲试验
Eur Urol. 2024 Mar;85(3):229-238. doi: 10.1016/j.eururo.2023.08.012. Epub 2023 Sep 29.
3
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.JAVELIN Bladder Medley 试验：avelumab 为基础的联合方案作为晚期尿路上皮癌的一线维持治疗。
Future Oncol. 2024 Feb;20(4):179-190. doi: 10.2217/fon-2023-0492. Epub 2023 Sep 6.
4
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.雷莫芦单抗联合帕博利珠单抗治疗既往治疗的晚期非小细胞肺癌、胃食管交界处癌或尿路上皮癌患者（JVDF）：一项多队列、非随机、开放标签、1a/1b 期临床试验。
Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.
5
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?恩福妥单抗和帕博利珠单抗联合治疗在尿路上皮癌中的相关变革：还有什么遗留问题？
Med. 2024 Jun 14;5(6):490-492. doi: 10.1016/j.medj.2024.04.006.
6
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.培美曲塞二钠与吉西他滨用于晚期尿路上皮癌的2期试验（E4802）：东部肿瘤协作组的一项试验
Cancer. 2008 Jun 15;112(12):2671-5. doi: 10.1002/cncr.23503.
7
LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
Eur Urol. 2024 Mar;85(3):239-241. doi: 10.1016/j.eururo.2023.11.010. Epub 2023 Nov 25.
8
Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.一线系统治疗联合免疫疗法治疗晚期或转移性尿路上皮癌的最新进展和未来方向：治疗演变的历史视角。
Int J Clin Oncol. 2024 Aug;29(8):1096-1104. doi: 10.1007/s10147-024-02526-y. Epub 2024 Jun 8.
9
A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.纳武单抗联合紫杉醇治疗晚期尿路上皮癌的2期试验
J Urol. 2023 Jan;209(1):121-130. doi: 10.1097/JU.0000000000002969. Epub 2022 Nov 1.
10
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.单药紫杉烷与含紫杉烷联合化疗作为晚期尿路上皮癌挽救治疗的对比
Eur Urol. 2016 Apr;69(4):634-641. doi: 10.1016/j.eururo.2015.07.042. Epub 2015 Aug 8.
本文引用的文献
1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
2
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.帕博利珠单抗联合或不联合乐伐替尼作为晚期尿路上皮癌患者的一线治疗（LEAP-011）：一项3期随机双盲试验
Eur Urol. 2024 Mar;85(3):229-238. doi: 10.1016/j.eururo.2023.08.012. Epub 2023 Sep 29.
3
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.一线帕博利珠单抗治疗铂类药物治疗禁忌的局部晚期和不可切除或转移性尿路上皮癌患者（KEYNOTE-052）：一项多中心、单臂、2 期研究。
Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.
4
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.治疗不适合顺铂为基础化疗的转移性尿路上皮癌患者。
J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9.
Zotero 插件